13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001746382
Total reported value
$47.5M
$47.5M
66 檔
174.7%
During the Q2 2024 filing period, Altium Capital Management LLC (CIK: 0001746382) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $47.5M across 66 reported positions.
During Q2 2024, Altium Capital Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including VERA, ADMA, XENE) accounted for 174.7% of total reported equity market value during Q2 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VERA | Vera Therapeutics Inc | Stock-Other | 10.54% | — | +0.56% | |
| 2 | ADMA | Adma Biologics Inc | Stock-Healthcare | 6.89% | — | -1.95% | |
| 3 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 5.74% | — | +3.62% | |
| 4 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 5.39% | — | +70.80% | |
| 5 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 5.28% | — | — | |
| 6 | INSM | Insmed Inc | Stock-Healthcare | 5.19% | — | +58.33% | |
| 7 | ✓ | Alimera Sciences Inc | Stock-Other | 4.88% | — | -15.69% | |
| 8 | SKYE | Skye Bioscience Inc | Stock-Other | 4.41% | — | — | |
| 9 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.04% | — | — | |
| 10 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.54% | — | +39.24% | |
| 11 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 3.50% | — | — | |
| 12 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 3.16% | — | — | |
| 13 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 3.08% | — | — | |
| 14 | RZLT | Rezolute Inc | Stock-Other | 2.98% | — | — | |
| 15 | ASND | Ascendis Pharma A/S | Stock-Other | 2.78% | — | +100.00% | |
| 16 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 2.64% | — | +43.53% | |
| 17 | LRMR | Larimar Therapeutics Inc | Stock-Other | 2.63% | — | +27.91% | |
| 18 | SVRA | Savara Inc | Stock-Other | 2.62% | — | +19.48% | |
| 19 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 2.32% | — | +240.42% | |
| 20 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.06% | — | — | |
| 21 | XTNT | Xtant Medical Holdings Inc | Stock-Other | 1.91% | — | -3.04% | |
| 22 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.64% | — | -63.77% | |
| 23 | REAL | Realreal Inc/the | Stock-Other | 1.63% | — | +56.28% | |
| 24 | CYBNEUR | Cybin Inc | Stock-Other | 1.54% | — | — | |
| 25 | OTLK | Outlook Therapeutics Inc | Stock-Other | 1.51% | — | — | |
| 26 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.17% | — | — | |
| 27 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.17% | — | — | |
| 28 | VERUEUR | Veru Inc | Stock-Other | 0.78% | — | +7.81% | |
| 29 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.78% | — | — | |
| 30 | MIST | Milestone Pharmaceuticals In | Stock-Other | 0.55% | — | -16.53% | |
| 31 | ACHV | Achieve Life Sciences Inc | Stock-Other | 0.41% | — | -74.11% | |
| 32 | ✓ | Allurion Technologies Inc | Stock-Other | 0.39% | — | — | |
| 33 | ANVS | Annovis Bio | Stock-Other | 0.36% | — | — | |
| 34 | ✓ | Biovie Inc | Stock-Other | 0.32% | — | -34.20% | |
| 35 | CNTX | Context Therapeutics Inc | Stock-Other | 0.29% | — | — | |
| 36 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.26% | — | — | |
| 37 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.25% | — | — | |
| 38 | FATBW | Fat Brands Inc -cw25 | Stock-Other | 0.23% | — | — | |
| 39 | APRE | Aprea Therapeutics Inc | Stock-Other | 0.23% | — | — | |
| 40 | SPRU | Spruce Power Holding Corporation | Stock-Other | 0.17% | — | -29.46% | |
| 41 | EVOKEUR | Evoke Pharma Inc | Stock-Other | 0.15% | — | -4.48% | |
| 42 | BOLD | Boundless Bio Inc | Stock-Other | 0.13% | — | -58.43% | |
| 43 | LXRX | Lexicon Pharmaceuticals Inc | Stock-Other | 0.08% | — | — | |
| 44 | GBS1EUR | Gbs Inc | Stock-Other | 0.07% | — | — | |
| 45 | PMNT | Perfect Moment LTD | Stock-Other | 0.06% | — | -31.86% | |
| 46 | NXGLW | Nexgel Inc -cw26 | Stock-Other | 0.04% | — | — | |
| 47 | CETXEUR | Cemtrex Inc | Stock-Other | 0.03% | — | — | |
| 48 | ✓ | Wearable Devices LTD | Stock-Other | 0.03% | — | — | |
| 49 | ✓ | Quoin Pharmaceuticals LTD | Stock-Other | 0.02% | — | +55.69% | |
| 50 | ONFOW | Onfolio Holdings Inc -27 | Stock-Other | 0.02% | — | — |
According to official SEC Form 13F filings, Altium Capital Management LLC reported a total U.S. public equity portfolio value of $47.5M across 66 disclosed positions in Q2 2024.
During Q2 2024, Altium Capital Management LLC's top holdings by market value included VERA (10.5%)、ADMA (6.9%)、XENE (5.7%). The largest single position, VERA, represented 10.5% of total portfolio value.
In Q2 2024, Altium Capital Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.